Pharma channel feed – Endpoints News

Pharma channel feed

Citizen petitions: FDA revises guidance to block drugmakers from abusing the system

7 years ago

A go-go FDA is poised to break the all-time record on new drug approvals. Is this the new standard for biopharma success?

7 years ago

Paratek caps 20-year R&D journey with FDA OK for its broad spectrum antibiotic — time to talk launch

7 years ago

UK alarm bells are ringing as a biotech cuts a few trial sites, fretting over Brexit’s impact on drug development

7 years ago

Gurnet Point-backed Boston Pharmaceuticals supercharges pipeline with twin deals grabbing top cast-offs from GSK, Novartis

7 years ago

Eli Lilly steers URLi toward the FDA after scoring positive results in a pair of PhIII diabetes trials

7 years ago

Giving it a GO: Giant Roche selects a tiny player at LabCentral for its next cancer R&D partner

7 years ago

Bucking the trend, Antares gains FDA OK for testosterone injection on second try

7 years ago

Insmed follows a new pathway at the FDA for antibacterials, winning quick OK for Arikayce

7 years ago

Merck’s cancer R&D juggernaut ties up to little Dragonfly’s natural born killer platform — with billions on the line

7 years ago

Ex-Kerrisdale analyst sets out to torpedo Nektar with a blunt short attack on star drug NKTR-214: 'It doesn’t work'

7 years ago

A speedy FDA offers lightning review and quick OK for the latest PD-1 from Regeneron and Sanofi

7 years ago

Pfizer nabs fast OK for a new frontline lung cancer drug as pharma giant shows off its new R&D strategy

7 years ago

Watch out Amgen and Teva, Eli Lilly got its green light for a rival CGRP migraine drug — and they’re coming after you

7 years ago

Eli Lilly picks up an oral GLP-1 diabetes drug from a big Roche sub for $50M in cash-plus deal — and it’s not a peptide

7 years ago

AMAG expands maternal health pipeline, bags late-stage orphan drug for $12.5M

7 years ago

Gilead's storied hep C franchise will now include a generic drug operation

7 years ago

Researchers point to R&D treaty to spur new infectious disease treatments

7 years ago

Unwanted by AbbVie and Infinity, battered Verastem gets an OK for duvelisib and a second shot at success

7 years ago

FDA lifts clinical hold on Sarepta's Duchenne MD gene therapy, clearing the way to a quick launch of a pivotal trial

7 years ago

FDA gives Epizyme a green light on trial recruitment, but tazemetostat isn’t completely out of the woods yet

7 years ago

Giant Amgen joins a nascent effort to build a new biotech hub in LA

7 years ago

European regulators are locking the door on Sarepta’s Duchenne drug — but they aren’t throwing away the key

7 years ago

Dismissing critical reports on patient deaths, FDA says safety/effectiveness of Nuplazid holds up under review

7 years ago

First page Previous page 290 291 292293294 295 296 Next page Last page